Comparison between “early” or “late” intravitreal injection of dexamethasone implant in branch (BRVO) or central (CRVO) retinal vein occlusion: six-months follow-up

References

• Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 2006;124:726–732
   PubMed Web of Science ®Google Scholar
• Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 2013;120:106–114
   PubMed Web of Science ®Google Scholar
• Eye Disease Case-Control Study Group. Risk factors for branch retinal vein occlusion. Am J Ophthalmol 1993;116:286–296
   PubMed Web of Science ®Google Scholar
• Ashraf M, Souka AA, Singh RP. Central retinal vein occlusion: modifying current treatment protocols. Eye (Lond) 2016;30:505–514
   PubMed Web of Science ®Google Scholar
• Campa C, Alivernini G, Bolletta E, et al. Anti-VEGF therapy for retinal vein occlusions. Curr Drug Targets 2016;17:328–336
   PubMed Web of Science ®Google Scholar
• Song WT, Xia XB. Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment. BMC Ophthalmol 2015;15:31
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336–339
   PubMed Web of Science ®Google Scholar
• Pacella E, Turchetti P, Artico M, et al. Adverse events associated with intraocular injection of anti-VEGF(bevacizumab) in retinal vein occlusion: a case report. Neuro-Ophthalmol Visual Neurosci 2015;1:22–26
   Google Scholar
• Thom HH, Capkun G, Nixon RM, Ferreira A. Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion. BMC Med Res Methodol 2014;14:140
   PubMed Web of Science ®Google Scholar
• Nghiem-Buffet S, Fajnkuchen F, Buffet M, et al. Intravitreal ranibizumab and/or dexamethasone implant for macular edema secondary to retinal vein occlusion . Ophthalmologica 2014;232:216–222
   PubMed Web of Science ®Google Scholar
• Glanville J, Patterson J, McCool R, et al. Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review. BMC Ophthalmol 2014;14:7
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R, Jr et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134–1146. E1133
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240:782–783
   PubMed Web of Science ®Google Scholar
• Jain N, Stinnett SS, Jaffe GJ. Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results. Ophthalmology 2012;119:132–137
   PubMed Web of Science ®Google Scholar
• Koss MJ, Pfister M, Rothweiler F, et al. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol 2012;90:e98–e103
   PubMed Web of Science ®Google Scholar
• Wang K, Wang Y, Gao L, et al. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 2008;31:1541–1546
   PubMed Web of Science ®Google Scholar
• Pfister M, Rothweiler F, Michaelis M, et al. Correlation of inflammatory and proangiogenic cytokines from undiluted vitreous samples with spectral domain OCT scans, in untreated branch retinal vein occlusion. Clin Ophthalmol 2013;7:1061–1067
   PubMedGoogle Scholar
• Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52:80–86
   PubMed Web of Science ®Google Scholar
• Augustin AJ, Kuppermann BD, Lanzetta P, Ozurdex MEAD Study Group, et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmol 2015;15:150
   PubMed Web of Science ®Google Scholar
• Central Retinal Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997;115:486–491
   PubMedGoogle Scholar
• McIntosh RL, Rogers SL, Lim L, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010;117:1113–1123. E1115
   PubMed Web of Science ®Google Scholar
• Pacella E, Vestri AR, Muscella R, et al. Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema. Clin Ophthalmol 2013;7:1423–1428
   PubMedGoogle Scholar
• Natarajan S. Managing patients with retinal vein occlusions: is there any real step forward?. Indian J Ophthalmol 2012;60:251–254
   PubMed Web of Science ®Google Scholar
• Pacella E, Pacella F, La Torre G, et al. Testing the effectiveness of intravitreal ranibizumab during 12 months of follow-up in venous occlusion treatment . Clin Ter 2012;163:e413–e222
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmernam B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001;131:61–77
   PubMed Web of Science ®Google Scholar
• Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 2008;86:372–376
   PubMed Web of Science ®Google Scholar
• Avery RL. Regression of retinal and iris neovascularisation after intravitreal injection of bevacizumab (avastin) treatment. Retina 2006;26:352–354
   PubMed Web of Science ®Google Scholar
• Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279–284
   PubMed Web of Science ®Google Scholar
• Chiquet C, Bron AM, Straub M, et al. Retinal vein occlusions: therapeutic switch in macular oedema treatment with a 12-month follow-up . Ophthalmic Res 2016;55:152–158
   PubMed Web of Science ®Google Scholar
• Mayer K, Keese M, Schmandra TC, et al. Diagnosis and therapy of deep vein thrombosis. MMW Fortschr Med 2012;154:79–83
   PubMedGoogle Scholar
• Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005;24:493–519
   PubMed Web of Science ®Google Scholar
• Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost 2010;8:1886–1894
   PubMed Web of Science ®Google Scholar
• Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115–1128
   PubMed Web of Science ®Google Scholar
• de Smet MD. Corticosteroid intravitreal implants. Dev Ophthalmol 2012;51:122–133
   PubMedGoogle Scholar
• Gewaily D, Muthuswamy K, Greenberg PB. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 2015;9:CD007324
   Google Scholar